OraSure Technologies (OSUR) Stock Price

OraSure Technologies Price

NASDAQ·CLOSED
3.84USD-0.18 (-4.58 %)
Market closed

Revenue has compounded at 2.8% per year over the past 19 years to 115.02 M USD. Earnings per share have grown at 11.4% per year over the last 17 years. OraSure Technologies's net margin stands at -59.8%, down from -9.8% several years earlier. Analysts set a median price target of 4.59 USD, implying 19.5% above the current price. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 82% above its 52-week low.

OraSure Technologies stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of OraSure Technologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how OraSure Technologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing OraSure Technologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

OraSure Technologies Stock Price History
DateOraSure Technologies Price
8/14/20263.84 USD
8/13/20264.02 USD
8/12/20263.75 USD
8/11/20263.88 USD
8/10/20264.00 USD
8/7/20264.05 USD
8/6/20264.00 USD
8/5/20264.11 USD
8/4/20264.09 USD
8/3/20264.16 USD
7/31/20264.05 USD
7/30/20263.97 USD
7/29/20263.98 USD
7/27/20264.01 USD
7/23/20264.03 USD
7/22/20263.79 USD
7/21/20263.80 USD
7/20/20263.85 USD
7/17/20263.87 USD
7/16/20263.96 USD
7/15/20264.25 USD
7/14/20264.26 USD
7/13/20264.27 USD
7/10/20264.30 USD
7/9/20264.28 USD
7/8/20264.19 USD
7/7/20264.32 USD
7/6/20264.36 USD
7/2/20264.35 USD
7/1/20264.32 USD
6/30/20264.46 USD
6/29/20264.50 USD
6/26/20264.46 USD
6/25/20264.41 USD
6/24/20264.34 USD
6/23/20264.24 USD
6/22/20264.15 USD
6/18/20264.25 USD
6/17/20264.47 USD
6/16/20264.32 USD
6/15/20264.17 USD
6/12/20264.18 USD
6/11/20264.19 USD
6/10/20264.26 USD
6/9/20264.24 USD
6/8/20264.15 USD
6/5/20264.04 USD
6/4/20264.17 USD
6/3/20263.95 USD
6/2/20264.00 USD
6/1/20264.09 USD
5/29/20264.30 USD
5/28/20264.23 USD
5/27/20263.98 USD
5/26/20263.94 USD
5/22/20263.61 USD
5/21/20263.29 USD
5/20/20263.07 USD
5/19/20263.08 USD
5/18/20263.01 USD
5/15/20263.00 USD
5/14/20262.95 USD
5/13/20263.04 USD
5/12/20262.97 USD
5/11/20263.02 USD
5/8/20263.06 USD
5/7/20263.13 USD
5/6/20263.00 USD
5/5/20263.00 USD
5/4/20262.95 USD
5/1/20262.95 USD
4/30/20263.04 USD
4/29/20262.96 USD
4/28/20263.01 USD
4/27/20263.01 USD
4/24/20263.00 USD
4/23/20263.12 USD
4/22/20263.12 USD
4/21/20263.16 USD
4/20/20263.19 USD
4/17/20263.16 USD
4/16/20263.21 USD
4/15/20263.24 USD
4/14/20263.21 USD
4/13/20263.08 USD
4/10/20262.96 USD
4/9/20263.06 USD
4/8/20263.08 USD
4/7/20263.06 USD
4/6/20263.08 USD
4/2/20263.08 USD
4/1/20263.05 USD
3/31/20263.00 USD
3/30/20262.92 USD
3/27/20263.00 USD
3/26/20263.07 USD
3/25/20263.14 USD
3/24/20263.06 USD
3/23/20263.08 USD
3/20/20262.95 USD
3/19/20262.91 USD
3/18/20262.90 USD
3/17/20262.98 USD
3/16/20263.13 USD
3/13/20262.97 USD
3/12/20263.09 USD
3/11/20263.18 USD
3/10/20263.13 USD
3/9/20263.20 USD
3/6/20263.19 USD
3/5/20262.99 USD
3/4/20263.01 USD
3/3/20262.98 USD
3/2/20262.96 USD
2/27/20263.15 USD
2/26/20263.08 USD
2/25/20262.80 USD
2/24/20262.82 USD
2/23/20262.75 USD
2/20/20262.75 USD
2/19/20262.83 USD
2/18/20262.85 USD
2/17/20262.75 USD
2/13/20262.75 USD
2/12/20262.80 USD
2/11/20262.82 USD
2/10/20262.81 USD
2/9/20262.82 USD
2/6/20262.71 USD
2/5/20262.73 USD
2/4/20262.90 USD
2/3/20262.86 USD
2/2/20262.92 USD
1/30/20262.79 USD
1/29/20262.79 USD
1/28/20262.70 USD
1/27/20262.73 USD
1/26/20262.71 USD
1/23/20262.67 USD
1/22/20262.72 USD
1/21/20262.78 USD
1/20/20262.59 USD
1/16/20262.69 USD
1/15/20262.74 USD
1/14/20262.70 USD
1/13/20262.60 USD
1/12/20262.69 USD
1/9/20262.63 USD
1/8/20262.66 USD
1/7/20262.51 USD
1/6/20262.48 USD
1/5/20262.47 USD
1/2/20262.38 USD
12/31/20252.42 USD
12/30/20252.47 USD
12/29/20252.43 USD
12/26/20252.42 USD
12/24/20252.43 USD
12/23/20252.37 USD
12/22/20252.41 USD
12/19/20252.39 USD
12/18/20252.45 USD
12/17/20252.46 USD
12/16/20252.42 USD
12/15/20252.50 USD
12/12/20252.49 USD
12/11/20252.57 USD
12/10/20252.55 USD
12/9/20252.47 USD
12/8/20252.46 USD
12/5/20252.49 USD
12/4/20252.57 USD
12/3/20252.55 USD
12/2/20252.50 USD
12/1/20252.41 USD
11/28/20252.38 USD
11/26/20252.38 USD
11/25/20252.45 USD
11/24/20252.42 USD
11/21/20252.27 USD
11/20/20252.11 USD
11/19/20252.19 USD
11/18/20252.12 USD
11/17/20252.25 USD
11/14/20252.31 USD
11/13/20252.28 USD
11/12/20252.47 USD
11/11/20252.46 USD
11/10/20252.33 USD
11/7/20252.40 USD
11/6/20252.40 USD
11/5/20252.57 USD
11/4/20252.57 USD
11/3/20252.67 USD
10/31/20252.74 USD
10/30/20252.70 USD
10/29/20252.79 USD
10/28/20252.87 USD
10/27/20252.89 USD
10/24/20252.96 USD
10/23/20252.88 USD
10/22/20252.87 USD
10/21/20252.97 USD
10/20/20253.04 USD
10/17/20253.02 USD
10/16/20253.06 USD
10/15/20253.06 USD
10/14/20253.05 USD
10/13/20253.01 USD
10/10/20252.95 USD
10/9/20253.12 USD
10/8/20253.24 USD
10/7/20253.16 USD
10/6/20253.20 USD
10/3/20253.18 USD
10/2/20253.13 USD
10/1/20253.15 USD
9/30/20253.21 USD
9/29/20253.18 USD
9/26/20253.20 USD
9/25/20253.19 USD
9/24/20253.23 USD
9/23/20253.28 USD
9/22/20253.32 USD
9/19/20253.38 USD
9/18/20253.30 USD
9/17/20253.29 USD
9/16/20253.22 USD
9/15/20253.23 USD
9/12/20253.31 USD
9/11/20253.32 USD
9/10/20253.26 USD
9/9/20253.35 USD
9/8/20253.25 USD
9/5/20253.23 USD
9/4/20253.15 USD
9/3/20253.14 USD
9/2/20253.36 USD
8/29/20253.31 USD
8/28/20253.29 USD
8/27/20253.34 USD
8/26/20253.48 USD
8/25/20253.14 USD
8/22/20253.00 USD
8/21/20252.86 USD
8/20/20252.90 USD
8/19/20252.80 USD
8/18/20252.80 USD
Access this data via the Eulerpool API
Get Free API Key

OraSure Technologies Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
233.67 M USD
-11.65 M USD
-23.00 M USD
Jan 1, 2022
387.48 M USD
-5.24 M USD
-17.13 M USD
Jan 1, 2023
405.47 M USD
54.08 M USD
53.66 M USD
Jan 1, 2024
185.83 M USD
-20.60 M USD
-19.50 M USD
Jan 1, 2025
115.02 M USD
-68.12 M USD
-68.73 M USD
Jan 1, 2026 (e)
119.68 M USD
-14.81 M USD
-75.32 M USD
Jan 1, 2027 (e)
127.84 M USD
-15.82 M USD
-58.82 M USD
Jan 1, 2028 (e)
129.52 M USD
-16.02 M USD
-7.17 M USD

OraSure Technologies Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 16, 2026, 11:56 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
98.00106.00119.00128.00167.00181.00154.00171.00233.00387.00405.00185.00115.00119.00127.00129.00
12.648.1612.267.5630.478.38-14.9211.0436.2666.094.65-54.32-37.843.486.721.57
59.1862.2667.2368.7558.6862.4361.0459.0650.2138.2444.2041.0841.7441.7441.7441.74
58.0066.0080.0088.0098.00113.0094.00101.00117.00148.00179.0076.0048.0049.6753.0153.84
-20.00-10.008.0020.0027.0039.008.00-5.00-11.00-5.0054.00-20.00-68.00-14.00-15.00-16.00
-20.41-9.436.7215.6316.1721.555.19-2.92-4.72-1.2913.33-10.81-59.13-11.76-11.81-12.40
-11.00-4.008.0019.0030.0020.0016.00-14.00-22.00-17.0053.00-19.00-68.00-75.00-58.00-7.00
-26.67-63.64-300.00137.5057.89-33.33-20.00-187.5057.14-22.73-411.76-135.85257.8910.29-22.67-87.93
56.1856.1156.6857.2362.3762.5162.2072.8272.0473.2575.0174.4371.5771.5771.5771.57
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales OraSure Technologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue OraSure Technologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare OraSure Technologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares OraSure Technologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against OraSure Technologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

OraSure Technologies stock margins

The OraSure Technologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OraSure Technologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OraSure Technologies.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
50.33 %
-4.99 %
-9.84 %
Jan 1, 2022
38.31 %
-1.35 %
-4.42 %
Jan 1, 2023
44.25 %
13.34 %
13.23 %
Jan 1, 2024
41.02 %
-11.09 %
-10.49 %
Jan 1, 2025
41.90 %
-59.23 %
-59.76 %
Jan 1, 2026 (e)
41.90 %
-12.37 %
-62.93 %
Jan 1, 2027 (e)
41.90 %
-12.37 %
-46.01 %
Jan 1, 2028 (e)
41.90 %
-12.37 %
-5.54 %

OraSure Technologies Stock Revenue, EBIT, Earnings per Share

The OraSure Technologies earnings per share therefore indicates how much revenue OraSure Technologies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
3.24 USD
-0.16 USD
-0.32 USD
Jan 1, 2022
5.29 USD
-0.07 USD
-0.23 USD
Jan 1, 2023
5.41 USD
0.72 USD
0.72 USD
Jan 1, 2024
2.50 USD
-0.28 USD
-0.26 USD
Jan 1, 2025
1.61 USD
-0.95 USD
-0.96 USD
Jan 1, 2026 (e)
1.67 USD
-0.21 USD
-1.05 USD
Jan 1, 2027 (e)
1.78 USD
-0.22 USD
-0.82 USD
Jan 1, 2028 (e)
1.81 USD
-0.22 USD
-0.10 USD

OraSure Technologies business model & stock analysis

OraSure Technologies Inc. is a US company specializing in the development, manufacturing, and marketing of diagnostic medical products. It was founded in 1987 under the name SolarCare Technologies Corporation and changed its name to OraSure Technologies Inc. in 2000. The company's main goal is to reduce the prevalence of infectious diseases and improve global health. It focuses on four core areas: infectious diseases, microfluidic analysis, application management, and genomics. In the field of infectious diseases, OraSure Technologies Inc. produces various rapid tests for detecting diseases such as HIV, Hepatitis C, and Syphilis. It also offers tests for drug and alcohol consumption verification. In microfluidic analysis, the company produces devices and test kits for biomedical research and clinical use. These technologies allow for the quick analysis of small samples and accurate results. Application management is another important aspect of the company, offering cloud-based applications for optimized data and information management. These applications help businesses and institutions obtain real-time data and use data analytics tools. Additionally, OraSure Technologies Inc. is involved in genomics and offers various products and services related to DNA sequencing. The company has a broad customer base, ranging from government agencies and research institutions to service companies and private clinics. It operates in numerous countries worldwide. An example of a product from OraSure Technologies is the OraQuick HIV self-test, which allows individuals to determine within 20 minutes whether they are infected with the HIV virus or not. This is particularly important for people who cannot or do not want to visit a doctor and value their privacy. OraSure Technologies' history is marked by numerous innovations and significant milestones. One notable event was the development of the first oral HIV rapid test in 2004, which allowed for quick and reliable detection of the virus through a saliva sample instead of a blood sample. In recent years, the company has increased its investment in research and development and formed partnerships with companies and institutions to bring innovative diagnostic medical products to the market. In summary, OraSure Technologies Inc. is a leading US company specializing in the development, manufacturing, and marketing of diagnostic medical products. With a focus on infectious diseases, microfluidic analysis, application management, and genomics, the company has a wide range of products and a broad customer base. OraSure Technologies is an innovative company striving to improve global health through partnerships and investments in research and development.

OraSure Technologies SWOT Analysis

Strengths

OraSure Technologies Inc has several strengths that contribute to its success in the market. One notable strength is its strong product portfolio, which includes a range of innovative diagnostic tests and specimen collection devices. These products are highly reliable and have approval from regulatory authorities, offering customers confidence in their effectiveness.

Another strength is OraSure's commitment to research and development. By continually investing in new technologies and product improvements, the company stays ahead of the competition and can meet the evolving needs of the healthcare industry.

Weaknesses

Despite its strengths, OraSure Technologies Inc also faces some weaknesses. One significant weakness is its limited market presence outside of certain geographic regions. While the company enjoys strong brand recognition in certain markets, expanding its reach to new regions presents a challenge.

Additionally, OraSure relies on a few key customers for a significant portion of its revenue. This dependence on a few major clients exposes the company to potential risks if these customers were to reduce their orders or switch to competitors.

Opportunities

OraSure Technologies Inc has several opportunities to capitalize on in the market. One key opportunity is the growing demand for point-of-care diagnostic tests and their potential integration with telemedicine. By focusing on developing user-friendly and accurate point-of-care solutions, the company can tap into this expanding market segment.

Another opportunity lies in strategic partnerships and collaborations. By joining forces with other healthcare organizations or technology companies, OraSure can leverage complementary expertise and resources to enhance its product capabilities and enter new markets.

Threats

OraSure Technologies Inc faces various threats that could hinder its growth and market position. One significant threat is intense competition from both established players and emerging companies. To stay competitive, OraSure must continue to invest in research and development to differentiate itself and maintain its edge in the market.

Additionally, regulatory challenges and compliance requirements pose a threat to OraSure's operations. Changes in regulations or failure to comply with existing regulations could result in delays, increased costs, or the withdrawal of product approvals.

OraSure Technologies Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

OraSure Technologies Employees
Details
Date
OraSure Technologies Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

OraSure Technologies Segments

OraSure Technologies Revenue by Segment (1/5)

  • 3 Years

  • 5 Years

  • Max

Products and services
Other Revenues
Details
Date
Products and services
Other Revenues
Other
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
148.07 M USD
6.53 M USD
0.00 USD
Jan 1, 2020
166.38 M USD
5.34 M USD
0.00 USD
Jan 1, 2021
226.90 M USD
6.78 M USD
0.00 USD
Jan 1, 2022
378.05 M USD
9.43 M USD
0.00 USD

OraSure Technologies Revenue by Segment (2/5)

  • 3 Years

  • 5 Years

  • Max

Product
COVID-19
Genomics
HIV [ Member ]
HCV [ Member ]
Risk assessment testing
Royalty
Microbiome
Laboratory Services
Other Non Product Revenues
Other revenues
Royalty Income
Other product and services revenues
Details
Date
COVID-19 (1)
Product
COVID-19
Genomics
Molecular Sample Management Solutions (2)
HIV
HIV [ Member ]
Sample Management Solutions
HCV [ Member ]
Risk assessment testing
Royalty
Microbiome
Laboratory Services
Other Non Product Revenues
Other revenues
Non-product and services revenues
HCV
Royalty Income
Other product and services revenues
Molecular Services
Jan 1, 2018
0.00 USD
165.43 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
9.65 M USD
0.00 USD
0.00 USD
0.00 USD
6.66 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
243.33 M USD
54.34 M USD
0.00 USD
0.00 USD
38.81 M USD
0.00 USD
13.37 M USD
10.27 M USD
0.00 USD
7.50 M USD
7.30 M USD
6.75 M USD
0.00 USD
0.00 USD
0.00 USD
2.68 M USD
3.14 M USD
0.00 USD

OraSure Technologies Revenue by Segment (3/5)

  • 3 Years

  • 5 Years

  • Max

COVID-19
Genomics
Oraquick
Infectious disease testing
Oragene
Laboratory services
ORAcollect
Risk assessment testing
Other products
Intercept
Microbiome
Microbiome laboratory services
Histofreezer
OMNIgene® • GUT
Royalty income
Government Contract
Other Product and Services Revenues
Other non product revenues
Research and development funding
Grant funding
Charitable support reimbursement
Other product revenue
Details
Date
COVID-19
Genomics
Oraquick
Infectious disease testing
Oragene
Laboratory services
ORAcollect
Risk assessment testing
Other products
Intercept
Microbiome
Microbiome laboratory services
Histofreezer
OMNIgene® • GUT
Royalty income
Government Contract
Other Product and Services Revenues
Other non product revenues
Research and development funding
Grant funding
Charitable support reimbursement
Other product revenue
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
56.06 M USD
0.00 USD
46.70 M USD
0.00 USD
10.65 M USD
0.00 USD
9.52 M USD
8.11 M USD
0.00 USD
6.10 M USD
5.70 M USD
5.23 M USD
5.12 M USD
0.00 USD
0.00 USD
0.00 USD
851,000.00 USD
304,000.00 USD
261,000.00 USD
0.00 USD
Jan 1, 2020
49.80 M USD
37.14 M USD
0.00 USD
54.23 M USD
0.00 USD
9.56 M USD
0.00 USD
9.37 M USD
0.00 USD
0.00 USD
6.16 M USD
0.00 USD
0.00 USD
0.00 USD
3.43 M USD
0.00 USD
0.00 USD
1.91 M USD
0.00 USD
0.00 USD
0.00 USD
117,000.00 USD
Jan 1, 2021
76.87 M USD
63.35 M USD
0.00 USD
54.65 M USD
0.00 USD
11.84 M USD
0.00 USD
9.68 M USD
0.00 USD
0.00 USD
7.94 M USD
0.00 USD
0.00 USD
0.00 USD
4.42 M USD
0.00 USD
2.57 M USD
2.36 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
2.25 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

OraSure Technologies Revenue by Segment (4/5)

  • 3 Years

  • Max

Government Contract
Details
Date
Government Contract
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
561,000.00 USD
Jan 1, 2022
0.00 USD

OraSure Technologies Revenue by Segment (5/5)

  • 3 Years

  • 5 Years

  • Max

Diagnostics
Molecular Solutions
OSUR
DNAG
Details
Date
Diagnostics
Molecular Solutions
OSUR
DNAG
Jan 1, 2018
0.00 USD
0.00 USD
85.64 M USD
96.11 M USD
Jan 1, 2019
0.00 USD
0.00 USD
78.23 M USD
76.38 M USD
Jan 1, 2020
65.24 M USD
106.48 M USD
0.00 USD
0.00 USD
Jan 1, 2021
90.04 M USD
143.63 M USD
0.00 USD
0.00 USD
Jan 1, 2022
303.67 M USD
83.81 M USD
0.00 USD
0.00 USD

OraSure Technologies Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Other foreign countries
Africa
Europe
Other regions
Details
Date
United States
Other foreign countries
Africa
Europe
Other regions
Jan 1, 2018
136.85 M USD
33.83 M USD
0.00 USD
11.06 M USD
0.00 USD
Jan 1, 2019
107.28 M USD
35.57 M USD
0.00 USD
11.75 M USD
0.00 USD
Jan 1, 2020
130.84 M USD
28.82 M USD
0.00 USD
12.07 M USD
0.00 USD
Jan 1, 2021
188.38 M USD
31.49 M USD
0.00 USD
13.80 M USD
0.00 USD
Jan 1, 2022
350.21 M USD
0.00 USD
0.00 USD
11.54 M USD
25.74 M USD
Jan 1, 2023
361.66 M USD
0.00 USD
0.00 USD
8.11 M USD
35.70 M USD
Jan 1, 2024
139.16 M USD
0.00 USD
32.75 M USD
8.42 M USD
5.50 M USD
Jan 1, 2025
78.25 M USD
0.00 USD
23.99 M USD
7.39 M USD
5.38 M USD

OraSure Technologies Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

OraSure Technologies historical P/E ratio, EBIT multiple, and P/S ratio

OraSure Technologies annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

OraSure Technologies shares outstanding

The number of shares of OraSure Technologies was 71.57 M in 2025. This indicates how many shares OraSure Technologies is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
72.04 M Stocks
Jan 1, 2022
73.25 M Stocks
Jan 1, 2023
75.01 M Stocks
Jan 1, 2024
74.43 M Stocks
Jan 1, 2025
71.57 M Stocks
Jan 1, 2026 (e)
71.57 M Stocks
Jan 1, 2027 (e)
71.57 M Stocks
Jan 1, 2028 (e)
71.57 M Stocks

Current OraSure Technologies forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
66.67 % (6)
Hold
33.33 % (3)
Sell
0.00 % (0)
12M Price Target
4.59
Last Price
3.84
Currency
USD
12M Return Potential
19.53 %
LTM Return
0 %

OraSure Technologies Analyst Rating Actions

DateFirmActionRatingReliability
11/12/2025
Stephens & Co.
Stephens & Co.
MaintainedEqual Weight–
5/19/2025
Evercore ISI Group
Evercore ISI Group
MaintainedIn Line62
5/8/2025
Evercore ISI Group
Evercore ISI Group
MaintainedIn Line62
8/7/2024
Evercore ISI Group
Evercore ISI Group
MaintainedIn Line62
7/2/2024
Evercore ISI Group
Evercore ISI Group
MaintainedIn Line62
5/13/2024
JP Morgan
JP Morgan
MaintainedNeutral80
4/4/2024
Evercore ISI Group
Evercore ISI Group
MaintainedIn Line62
2/29/2024
JP Morgan
JP Morgan
MaintainedNeutral80
12/11/2023
Citigroup
Citigroup
MaintainedBuy48
11/8/2023
JP Morgan
JP Morgan
MaintainedNeutral80

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

OraSure Technologies Earnings Calls

2025

OraSure Technologies Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/11/2026-0.21USD-29.41 MUSD-2026 Q2
5/13/2026-0.20USD-28.23 MUSD-2026 Q1
2/25/2026-0.21USD-26.97 MUSD-2025 Q4
5/8/20240.02USD-60.45 MUSD-2024 Q1
2/12/20240.09USD-75.56 MUSD-2023 Q4
11/6/2023-0.11USD-51.64 MUSD-2023 Q3
8/7/2023-0.14USD-56.94 MUSD-2023 Q2
5/8/2023-0.12USD-67.02 MUSD-2023 Q1
2/21/20230.00USD-97.64 MUSD-2022 Q4
11/8/2022-0.04USD-93.08 MUSD-2022 Q3
...

EESG©

Eulerpool ESG Scorecard© for the OraSure Technologies stock

45/100
24
Environment
56
Social
56
Governance
E

Environment

20
Scope 1 - Direct Emissions1,148
Scope 2 - Indirect emissions from purchased energy1,944
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions3,091
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

OraSure Technologies shareholder structure

% Name
7.61389%
Private Management Group, Inc.
Private Management Group, Inc.
7.57700%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
5.81284%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.79524%
Neuberger Berman, LLC
Neuberger Berman, LLC
5.22632%
Altai Capital Management, L.P.
Altai Capital Management, L.P.
5.06937%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
...

OraSure Technologies Beneficial Ownership Filings (SEC 13D/G)

Free Float
93.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
19.30%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
19.04%
Wells Capital Management Incorporated
Wells Capital Management Incorporated
SEC ↗
14.50%
Wells Fargo Funds Management, LLC
Wells Fargo Funds Management, LLC
SEC ↗
11.00%
Samuel D. Isaly
Samuel D. Isaly
SEC ↗
11.00%
OrbiMed Capital LLC
OrbiMed Capital LLC
SEC ↗
7.30%
PRIVATE MANAGEMENT GROUP INC
PRIVATE MANAGEMENT GROUP INC
SEC ↗
7.20%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
6.40%
26-1080669
26-1080669
SEC ↗
6.01%
American Capital Management, Inc.
American Capital Management, Inc.
SEC ↗
6.00%
MANAGED ACCOUNT ADVISORS LLC000000000
MANAGED ACCOUNT ADVISORS LLC000000000
SEC ↗

OraSure Technologies Executives and Management Board

10 members · avg. age 58 · 40 % women

CM

Ms. Carrie Eglinton Manner (51)

President, Chief Executive Officer, Director · since 2022

5.60 M USD

Management

KM

Mr. Kenneth Mcgrath (53)

Chief Financial Officer

1.68 M USD
AM

Ms. Anne Messing

Chief Commercial Officer

–
JP

Mr. Jason Plagman

Vice President - Investor Relations · since 2023

–

Board of Directors

MA

Ms. Mara Aspinall (62)

Independent Chairman of the Board

219,998.00 USD
NG

Dr. Nancy Gagliano (65)

Independent Director · since 2021

193,333.00 USD
RM

Mr. Robert Mcmahon (56)

Independent Director

180,000.00 USD
LM

Mr. Lelio Marmora (58)

Independent Director

170,000.00 USD
HS

Hon Dr. David Shulkin (65)

Independent Director

170,000.00 USD
JK

Mr. John Kenny (56)

Independent Director

119,110.00 USD

Frequently asked questions about OraSure Technologies

OraSure Technologies Inc. operates under a diversified business model. The company specializes in the development, manufacturing, and distribution of point-of-care diagnostic and specimen collection devices. OraSure's products serve various industries, including healthcare, criminal justice, drug treatment, and public health. With a focus on innovative technologies, OraSure delivers solutions for rapid diagnostic testing, such as HIV and hepatitis C detection. The company also offers oral fluid collection devices for DNA testing and substance abuse monitoring. Through its comprehensive business model, OraSure Technologies Inc. remains committed to enhancing healthcare outcomes and improving overall testing processes.

OraSure Technologies Inc is primarily active in the biotechnology and healthcare industries.

The main competitors of OraSure Technologies Inc in the market are Abbott Laboratories, Quidel Corporation, and Hologic, Inc.

OraSure Technologies Inc. is a leading global provider of diagnostic testing and specimen collection devices. Founded in 1987, the company has a rich history of developing innovative solutions for infectious diseases and substance abuse testing. OraSure Technologies Inc. is focused on improving public health by offering non-invasive testing options that are accurate, reliable, and user-friendly. With a diverse portfolio of products, including the OraQuick® In-Home HIV Test and the OraCollect™ DNA Device, the company aims to empower individuals and healthcare professionals with effective tools for early detection and prevention. OraSure Technologies Inc. continues to drive advancements in diagnostics, making a significant impact on the healthcare industry.

OraSure Technologies Inc has achieved several significant milestones. One of the notable achievements is the development and FDA approval of the OraQuick® In-Home HIV Test, which is the first rapid HIV test that can be used by individuals in the comfort of their own homes. This groundbreaking product has helped to increase HIV testing rates and improve early detection. Additionally, OraSure Technologies Inc has made significant strides in the field of oral fluid diagnostics, paving the way for advancements in drug testing and healthcare diagnostics. The company continues to innovate and collaborate with industry partners, solidifying its position as a leader in the diagnostic testing space.

OraSure Technologies Inc is primarily present in the United States.

OraSure Technologies Inc represents core values of innovation, integrity, and excellence. With a strong corporate philosophy, the company strives to make a positive impact on healthcare by developing and providing innovative diagnostic tests and specimen collection devices. OraSure Technologies Inc is dedicated to improving public health outcomes through its commitment to quality, accuracy, and reliability. Through cutting-edge technologies and a focus on customer satisfaction, the company has become a leader in the industry, delivering accurate and rapid diagnostic solutions. OraSure Technologies Inc's dedication to constant innovation and maintaining the highest standards makes it a trusted name in the healthcare sector.

Analysts currently set an average price target of 4.59 USD for the OraSure Technologies stock (median: 4.59 USD), implying +19.5 % versus the latest price. The consensus is based on 9 analyst ratings.

OraSure Technologies Analyst Price Targets 2026

9 analysts currently rate the OraSure Technologies stock: 6 recommend buying, 3 holding and 0 selling. For 2026, analysts expect OraSure Technologies to generate revenue of 119.68 M USD and earnings per share of -1.05 USD.

OraSure Technologies Analyst Price Targets 2026

Converted at the current exchange rate, the OraSure Technologies share trades at 3.32 EUR (3.84 USD).

The OraSure Technologies share (OSUR) is listed on 4 stock exchanges, including: NASDAQ (OSUR), Frankfurt (EP3.F), München (EP3.MU), SIX (Zürich) (EP3.SW).

OraSure Technologies Inc is a US company specializing in the development and marketing of diagnostic tests, devices, and medical accessories. It was founded in 2000 as a spin-off of Epitope Inc. Currently, OraSure Technologies Inc employs over 500 employees and is headquartered in Bethlehem, Pennsylvania. The company's business model is based on various divisions focusing on different medical applications. These include divisions such as "Infectious Diseases," "Clinical Laboratory Diagnostics," and "Molecular Diagnostics." In the Infectious Diseases division, OraSure Technologies Inc offers various tests for detecting infections, including the OraQuick® HCV Rapid Antibody Test, a test for the rapid and easy detection of Hepatitis C antibodies in the blood. The company also manufactures the OraQuick® HIV Self-Test and the OraQuick® In-Home HIV Test, which provide a simple and convenient way for patients to test themselves for HIV. The Clinical Laboratory Diagnostics division focuses on the development of diagnostic tests for use in clinical laboratories. OraSure Technologies Inc offers products such as the Intercept® i2F Body Fluid Collection Device and the Intercept® Oral Fluid Drug Test, which enable fast and reliable analysis of various body fluids. The Molecular Diagnostics division focuses on the development of molecular biological tests for detecting diseases based on DNA and RNA analysis. The company offers products such as the OraSure® OMNIgene® GUT Kit for stabilizing DNA samples and the OraQuick® Ebola Rapid Antigen Test, which allows for rapid and reliable detection of Ebola antigens. In addition to the development and marketing of diagnostic tests and devices, OraSure Technologies Inc also offers medical diagnostic accessories. These include the Intercept® Collection Kit and the OraSure® Sample Collection Device, which enable reliable and secure sample collection for blood tests and other examinations. OraSure Technologies Inc's business model is based on a strong focus on research and development of new products, as well as the safe and reliable production of diagnostic tests and devices for use in medical facilities. Through close collaboration with leading medical research institutes and universities, OraSure Technologies Inc is able to develop innovative and groundbreaking products for medical diagnostics, making an important contribution to healthcare and disease prevention.

The expected revenue of OraSure Technologies is 119.68 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of OraSure Technologies is -75.32 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of OraSure Technologies is currently -3.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the OraSure Technologies stock.

The price-to-sales ratio (P/S) of OraSure Technologies is currently 2.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the OraSure Technologies stock.

The Eulerpool Quality Score for OraSure Technologies is 1/10.

The ISIN of OraSure Technologies is US68554V1089. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of OraSure Technologies is 881351. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of OraSure Technologies is OSUR. The ticker symbol is used to trade OraSure Technologies shares on the stock exchange.

OraSure Technologies paid dividends every year for the past 0 years.

OraSure Technologies is assigned to the 'Health' sector.

The dividends of OraSure Technologies are distributed in USD.

All fundamentals and in-depth analysis of OraSure Technologies

Our stock analysis for OraSure Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OraSure Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

OraSure Technologies Stock
OraSure Technologies Revenue→
OraSure Technologies Stock
OraSure Technologies Net Income→
OraSure Technologies Stock
OraSure Technologies P/E→
OraSure Technologies Stock
OraSure Technologies P/S→
OraSure Technologies Stock
OraSure Technologies EBIT→
OraSure Technologies Stock
OraSure Technologies Dividend→
OraSure Technologies Stock
OraSure Technologies Directors Dealings→
OraSure Technologies Stock
OraSure Technologies Stocks→
OraSure Technologies Stock
OraSure Technologies Market capitalization→
OraSure Technologies Stock
OraSure Technologies Debt→
OraSure Technologies Stock
OraSure Technologies Liabilities→
OraSure Technologies Stock
OraSure Technologies Equity→
OraSure Technologies Stock
OraSure Technologies AAQS→
OraSure Technologies Stock
OraSure Technologies Employees→
OraSure Technologies Stock
OraSure Technologies ROE→
OraSure Technologies Stock
OraSure Technologies ROA→
OraSure Technologies Stock
OraSure Technologies ROCE→
OraSure Technologies Stock
OraSure Technologies News→
OraSure Technologies Stock
OraSure Technologies Analyst Price Targets→

Health Stocks

Orchestra Biomed HoldingsOramed PharmaceuticalsOrchid PharmaOragenicsOrexoOpus GeneticsOrganigram GlobalOptus Pharmaceutical CoOrganiGram HoldingsOptomed OyjOrganogenesis HoldingsOptiscan ImagingAll Stocks A–Z →